JFL LIFE SCIENCES LIMITED

Just For Life

August 10Th, 2026

To,
The Manager,
Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

NSE Symbol: JFLLIFE; ISIN: INE0LA901015

Subject: Outcome of Board Meeting held on Monday, August 10, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of JFL Life Sciences Limited ("the Company") has been held on August 10, 2026, at 02:00 P.M. which concluded at 05:25 PM and Board has approved the following:

1. Unaudited financial results for year ended June 30, 2026 along with Limited Review Report.

Thanking You
Yours Truly,
For JFL LIFE SCIENCES LIMITED

PATEL SMIRAL A

Digitally signed by PATEL SMIRAL A
Date: 2026.08.10 17:26:27 +05'30'

SMIRAL ASHWINKUMAR PATEL
Managing director
DIN: 00769486

Encl: A/a

Independent Auditor's Review Report on the Quarter Ended June 30, 2026, Unaudited Financial Results of JFL LIFE SCIENCES LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
JFL LIFE SCIENCES LIMITED
309, Satyam Mall, Opp. Saman Complex,
Nr. Vishweshwar Mahadev Mandir, Settelite,
Ahmedabad, Gujrat, India, 380015

1. We have reviewed the accompanying statement of unaudited financial results of **JFL Life Sciences Limited** (the 'Company') for the quarter ended June 30, 2026 (the "Statement"). This statement is prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

   A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doshi Doshi & Co**,
Chartered Accountants
Firm Registration No.: 153683W

C.R. Doshi

DOSHI DOSHI & CO. FRN : 153683W Chartered Accountants

Chintan R. Doshi
Partner
Membership No.:158931
UDIN: 26158931SSPPSQ3420

Place: Ahmedabad
Date: August 10, 2026

9167 404 303
chintan@ddco.in
www.ddco.in

Ahmedabad Branch
C 908, Stratum @ Venus Ground,
NR Jhansi Ki Rani Statue,
Nehrunagar, Ahmedabad - 380015

Mumbai Branch
119, Plot No. 7, Near F M Banquets,
Udyog Nagar, Goregaon West,
Mumbai - 400104.

JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015

Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2026

(Rs. In Lakhs)

Sr. No.	PARTICULARS	Quarter Ended on			Year Ended on
		30.06.2026 (Unaudited)	31.03.2026 (Refer Note 4)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
	INCOMES				
I	Revenue from Operations	1,110.25	6,305.44	1,158.54	13,138.26
II	Other Income	1.78	4.03	0.28	6.90
III	Total Income (I + II)	**1,112.02**	**6,309.47**	**1,158.82**	**13,145.16**
IV	**EXPENSES**				
(a)	Cost of materials consumed	740.19	5,781.90	759.23	11,505.53
(b)	Changes of Inventories of Finished Goods, Work in Progress, Stock in Trade	(61.55)	(0.46)	8.10	(7.52)
(c)	Employee benefits expense	27.61	35.11	23.21	111.56
(d)	Finance Cost	30.16	103.43	24.48	210.59
(e)	Depreciation and Amortisation Expense	31.81	27.43	26.40	107.52
(f)	Other Expenses	194.68	137.33	174.65	357.57
	TOTAL EXPENSES (IV) (a to f)	**962.90**	**6,084.74**	**1,016.06**	**12,285.26**
V	**Profit/(Loss) before Exceptional Items and Tax (III-IV)**	**149.12**	**224.73**	**142.76**	**859.90**
VI	Exceptional Items & Extraordinary Item	-	-	-	-
VII	**Profit/ (Loss) Before Tax (V-VI)**	**149.12**	**224.73**	**142.76**	**859.90**
VIII	**TAX EXPENSES**				
(a)	Current Tax	37.57	53.17	22.61	215.82
(b)	Deffered Tax	0.17	5.69	45.54	3.98
	Total Tax Expenses	**37.75**	**58.86**	**68.15**	**219.80**
IX	**NET PROFIT / (LOSS) AFTER TAX**	**111.37**	**165.87**	**74.61**	**640.10**
X	**Items that will not be reclassified to profit or loss**				
(i)	Re-measurement gains / (loss) on defined benefit plans	(0.28)	0.53	(0.09)	1.70
(ii)	Income tax relating to items that will not be reclassified to profit or loss	0.07	(0.13)	0.02	(0.43)
	Other comprehensive income, net of tax	**(0.21)**	**0.39**	**(0.07)**	**1.27**
	Total comprehensive income for the quarter / year	**111.16**	**166.27**	**74.54**	**641.38**
XI	Paid up Equity Share Capital	**3,299.53**	**3,299.53**	**3,299.53**	**3,299.53**
	(Rs. 10 Face value per share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XII	Other Equity				1,287.39
XIII	**Earning Per Share (In Rupees)**				
(i)	Basic	0.34	0.50	0.23	1.94
(ii)	Diluted	0.34	0.50	0.23	1.94

NOTES:

1. These financial result were reviewed by the Board of Directors and Audit Committee thereafter have been approved by the board of directors at its meeting held on August 10, 2026. The Statutory Auditors have carried out review of the unaudited financial result for the quarter ended on June 30, 2026.
2. Financial results for all the periods presented have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
3. Company has only one reportable segment - Pharmaceuticals Manufacturing.
4. The figures for Quarter ended March 31, 2026 are the balancing figures between audited figures in respect to the full Financial Year up to March 31, 2026 and the unaudited published year to date figures up to December 31, 2025 being the date of the end of the third quarter of financial year which were subjected to limited review.
5. Figures for the previous period have been regrouped/ rearranged/ reclassfied wherever considered necessary to correspond with the current period's classification/group's disclosure.

For JFL Life Sciences Limited

Smiral A. Patel
Managing Director
DIN : 00769486
Date : August 10, 2026
Place : Ahmedabad

JFL Life Sciences Limited